Last updated: 11/07/2018 11:02:47

Crossover study to evaluate the comparative bioavailability of two fixed dose combination tablet formulations of extended release metformin and extended release glimepiride in health volunteers

Request patient level data
GSK study ID
116806
See study documents
Clinicaltrials.gov ID
NCT01725672
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Other
Other
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: An Open-Label, Randomized, Single Dose, Four-way Crossover, Multi-stage Study to determine the Comparative Bioavailability of two fixed dose combination tablet formulations, 500 mg or 1000 mg extended release metformin and 1 mg or 2 mg extended release glimepiride, in healthy adult male and female subjects in the fed state
Trial description: This is a an open-label, randomized, single dose, four-way crossover, multi-stage study enrolling 20 healthy adult male and female subjects per part. This study consists of two separate parts (Part A and B) with each part comprising four treatment periods. Each subject will participate in all four treatment periods per part; Subjects may not enrol in both Parts A and B.
This study is being conducted to compare the pharmacokinetics (PK) of two extended release fixed dose combinations (FDC) oral formulations of metformin and glimepiride at two doses, 500mg/1mg and 1000mg/2mg, with each FDC formulation to be administered orally as a single dose and compared with the commercially available formulations of metformin extended release (XR) (GLUCOPHAGE ™ Sustained Release [SR]) and glimepiride immediate release (IR) (AMARYL ™).
Part A of study will evaluate the bioavailability of a formulation comprising a film coated tablet containing release controlling polymers; and Part B will evaluate the bioavailability of a formulation comprising a tablet coated with release controlling polymers.
In each part there will be 4 treatment periods. During each period, subjects will be randomized sequentially to receive a single dose of a reference treatment of 500 mg metformin XR / 1 mg glimepiride IR; and a reference treatment of 1000 mg metformin XR / 2 mg glimepiride IR; and an FDC tablet containing 500 mg metformin XR and 1 mg glimepiride XR; and an FDC tablet containing 1000 mg metformin XR and 2 mg glimepiride XR.Serial PK sampling for up to 36 hours and safety assessments will be performed. Each period will be separated by a washout period of at least 5 days and a follow-up visit will occur 14 days after the last dose of study drug.
Primary purpose:
Treatment
Trial design:
Crossover Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:

Cmax of metformin

Timeframe: At regular timepoints on Day 1 (0.5, 1, 1.5, ,2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24 hours post dose) and once at Day 2 (36 hours post dose) of each of the 4 treatment periods in Part A and Part B

AUC(0-t) and AUC(0-inf) for metformin and glimepiride

Timeframe: At regular timepoints on Day 1 (0.5, 1, 1.5, ,2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24 hours post dose) and once at Day 2 (36 hours post dose) of each of the 4 treatment periods in Part A and Part B

Secondary outcomes:

Tmax and t1/2 of of metformin and glimepiride

Timeframe: At regular timepoints on Day 1 (0.5, 1, 1.5, ,2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24 hours post dose) and once at Day 2 (36 hours post dose) of each of the 4 treatment periods in Part A and Part B

Percentage AUCex for metformin and glimepiride; and AUC(0-∞), AUC (0-t) for metformin and glimepiride in relevant treatments

Timeframe: At regular timepoints on Day 1 (0.5, 1, 1.5, ,2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24 hours post dose) and once at Day 2 (36 hours post dose) of each of the 4 treatment periods in Part A and Part B

Number of subjects with adverse events (AE)s

Timeframe: Participants will be followed and monitored for the duration of their hospital stay (24 hours per treatment period). The longest duration of participation in the study will be approximately 13 weeks

Interventions:
  • Drug: Metformin, 500 mg extended release tablet
  • Drug: Metformin, 1000 mg extended release tablet
  • Drug: Glimepiride, 1 mg immediate release tablet
  • Drug: Glimepiride, 2 mg immediate release tablet
  • Drug: Metformin, 500 mg and Glimepiride, 1 mg extended release film coated tablet containing release controlling polymers
  • Drug: Metformin, 1000 mg and Glimepiride, 2 mg extended release film coated tablet containing release controlling polymers
  • Drug: Metformin, 500 mg and Glimepiride, 1 mg extended release tablet coated with release controlling polymers
  • Drug: Metformin, 1000 mg and Glimepiride, 2 mg extended release tablet coated with release controlling polymers
    • Enrollment:
    20
    Primary completion date:
    Not applicable
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Campbell D, Patel R, Rhodes C, Whigham T, Farrier C, Palmer J, Bianco J, Everhart K, Clowes R, Roberts J, Govindarajan R. Development of a double extended release formulation of metformin and glimepiride . American Association of Pharmaceutical Scientists - 2014 Annual Meeting & Exposition. 2014;
    Medical condition
    Diabetes Mellitus, Type 2
    Product
    glimepiride, glimepiride/metformin, metformin
    Collaborators
    No
    Study date(s)
    September 2012 to August 2013
    Type
    Interventional
    Phase
    1

    Participation criteria

    Sex
    Female & Male
    Age
    18 - 65 years
    Accepts healthy volunteers
    Yes
    • Healthy male or female subjects between 18 and 65 years of age inclusive with body weight >= 50 kg and body mass index (BMI) within the range 19 to 32 kilogram/meter squared
    • Alanine aminotransferase (ALT) alkaline phosphatase and bilirubin <or=1.5x upper limit of normal (ULN).
    • The subject has a positive: drug/alcohol screen, Hepatitis, HIV screen
    • Abuse of alcohol
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Healthy male or female subjects between 18 and 65 years of age inclusive with body weight >= 50 kg and body mass index (BMI) within the range 19 to 32 kilogram/meter squared
    • Alanine aminotransferase (ALT) alkaline phosphatase and bilirubin
    • Normal ECG measurements. Average QT duration corrected for heart rate by Fridericia’s formula (QTcF) <450 millisecond or QTcF <480 msec in subjects with Bundle Branch Block based on an average from three electrocardiograms (ECGs) obtained over a brief recording period.
    • Female subjects of non-child bearing potential. Females of child bearing potential are eligible to enter if they are not pregnant and willing to use protocol-specified methods of contraception to prevent pregnancy until 14 days post-last dose of metformin/glimepiride.
    • Capable of giving written informed consent
    Exclusion criteria:
    • The subject has a positive: drug/alcohol screen, Hepatitis, HIV screen
    • Abuse of alcohol
    • Current or chronic history of liver disease, or known hepatic or biliary abnormalities
    • Exposure to more than four new investigational chemical entities within 12 months prior to the first dosing day
    • Participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)
    • Sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation
    • Donation of more than 500 mL blood within a 56 day period
    • Pregnant or lactating females
    • Unwillingness or inability to follow the procedures outlined in the protocol
    • Subject is mentally or legally incapacitated
    • Subject having positive urinary cotinine levels indicative of use of tobacco or nicotine-containing products within 6 months prior to screening.
    • Unable to refrain from consumption of red wine, Seville oranges, grapefruit or grapefruit juice from 7 days prior to the first dose
    • Subjects having asthma or are positive carbon monoxide (CO) on admission to the Unit
    • Unable to refrain from the use of prescription or non-prescription drugs within 7 days prior to first dose of study medication, unless approved by the Investigator and GSK Medical Monitor.

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    Randwick, New South Wales, Australia, 2031
    Status
    Study Complete
    Contact us

    Study documents

    Clinical study report
    Available language(s): English
    Download document(s)
    Scientific result summary
    Available language(s): English
    Download document(s)
    Protocol
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Refer to study documents

    Recruitment status
    Other
    Actual primary completion date
    Not applicable
    Actual study completion date
    2013-21-08

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Participate in clinical trial
    Additional information
    Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
    Click here
    Results for study 116806 can be found on the GSK Clinical Study Register.
    Click here
    Access to clinical trial data by researchers
    Visit website